Biogen Stock After Alzheimer’s Shake-Up: Bargain or Value Trap?

Biogen (BIIB) is undergoing a significant transition, reshaping its Alzheimer’s strategy and focusing on new drug launches amidst declining legacy product revenue. The article explores whether the stock is a value trap or a long-term growth opportunity, highlighting its volatility driven by neurology pipeline developments and Wall Street’s divided opinions. Investors need to consider Biogen’s complex risk-reward profile, its status as a widely held company with deep pipeline versus its valuation often reflecting binary event speculation.